These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32237290)

  • 1. Assessment of Amphetamine Withdrawal Symptoms of Lisdexamfetamine Dimesylate Treatment for Adults With Binge-Eating Disorder.
    Robertson B; Wu J; Fant RV; Schnoll SH; McElroy SL
    Prim Care Companion CNS Disord; 2020 Mar; 22(2):. PubMed ID: 32237290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.
    Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M
    JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age.
    Kornstein SG; Bliss C; Kando J; Madhoo M
    J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30817099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.
    McElroy SL; Hudson JI; Mitchell JE; Wilfley D; Ferreira-Cornwell MC; Gao J; Wang J; Whitaker T; Jonas J; Gasior M
    JAMA Psychiatry; 2015 Mar; 72(3):235-46. PubMed ID: 25587645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Apr; 69(4):410-21. PubMed ID: 25752762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder.
    McElroy SL; Hudson JI; Gasior M; Herman BK; Radewonuk J; Wilfley D; Busner J
    Int J Eat Disord; 2017 Aug; 50(8):884-892. PubMed ID: 28481434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.
    McElroy SL; Hudson J; Ferreira-Cornwell MC; Radewonuk J; Whitaker T; Gasior M
    Neuropsychopharmacology; 2016 Apr; 41(5):1251-60. PubMed ID: 26346638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.
    Gasior M; Hudson J; Quintero J; Ferreira-Cornwell MC; Radewonuk J; McElroy SL
    J Clin Psychopharmacol; 2017 Jun; 37(3):315-322. PubMed ID: 28383364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.
    Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL
    Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale.
    Yee KS; Pokrzywinski R; Hareendran A; Shaffer S; Sheehan DV
    Int J Methods Psychiatr Res; 2021 Mar; 30(1):e1849. PubMed ID: 32841462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisdexamfetamine: A Review in Binge Eating Disorder.
    Heo YA; Duggan ST
    CNS Drugs; 2017 Nov; 31(11):1015-1022. PubMed ID: 29134566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence.
    Ezard N; Dunlop A; Hall M; Ali R; McKetin R; Bruno R; Phung N; Carr A; White J; Clifford B; Liu Z; Shanahan M; Dolan K; Baker AL; Lintzeris N
    BMJ Open; 2018 Jul; 8(7):e020723. PubMed ID: 30030312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Banaschewski T; Johnson M; Lecendreux M; Zuddas A; Adeyi B; Hodgkins P; Squires LA; Coghill DR
    CNS Drugs; 2014 Dec; 28(12):1191-203. PubMed ID: 25139785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.
    Richards C; Iosifescu DV; Mago R; Sarkis E; Reynolds J; Geibel B; Dauphin M
    J Psychopharmacol; 2017 Sep; 31(9):1190-1203. PubMed ID: 28857719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.
    Ward K; Citrome L
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):229-238. PubMed ID: 29258368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.